Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Cimzia Drug Market size was valued at USD 2.8 billion in 2024 and is anticipated to surpass USD 11.5 billion by 2037, registering a CAGR of 12.5% during the forecast timeline i.e. 2025-2037. In 2025, the industry size of cimzia drug is evaluated at USD 3.1 billion.
The growth trajectory of the cimzia drug market is directed predominantly by the continued studies on the safety and efficacy of the drug in other indications. Experiential research on Cimzia's potential applications across a wide spectrum of autoimmune diseases, with regulators' support fuel further growth. For instance, in April 2025, Johnson & Johnson announced the new icotrokinra (JNJ-2113) results from its global Phase 3 clinical program and initiation of the first-ever head-to-head study in plaque psoriasis (PsO) to prove its superiority. It is a first-in-class investigational oral targeted peptide that selectively inhibits the IL-23 receptor and is under investigation in adults and adolescents aged ≥12 years with moderate-to-severe plaque PsO.
Furthermore, the trial-generated research and clinical confirmation contribute to spurring competition in the marketplace and constructing long-term expansion. Moreover, the strict conduct of clinical trials diversifies its therapeutic uses and elicits patients' confidence. For instance, in February 2024, a Phase 1b/2 clinical trial collaboration with Roche was announced to evaluate Immune-Onc's IO-108 in combination with Roche's atezolizumab and bevacizumab for the first-line treatment of patients with locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC).
Cimzia Drug Sector: Growth Drivers and Challenges
Growth Drivers
- Patient centric treatment modalities: Through focus on unique patient needs by customized treatment protocols and advanced drug delivery systems for increased convenience, the growth of Cimzia drug market is bolstered. For instance, in July 2023, Organon & Co. & Samsung Bioepis Co., Ltd. announced that HADLIMA (adalimumab-bwwd) was made available to patients in the U.S. In line with Humira, HADLIMA is offered in both citrate-free high concentration (100 mg/mL) and citrate-containing low concentration (50 mg/mL) to offer patients uninterrupted continuity of care.
- Drug acceptance for multiple health conditions: The Cimzia drug market is showing vigorous growth, due to its growing popularity across a sequence of autoimmune diseases. This broader therapeutic use benefits Cimzia in curing a vast population of patients and thus acts as a key driver in the expansion of the market. For instance, in October 2024, Johnson & Johnson (J&J) announced that it had acquired sole sales, marketing, and distribution rights of Remicade (infliximab) and Simponi (golimumab) in the UK. It is an anti‑inflammatory drug used to treat a variety of autoimmune diseases such as rheumatoid arthritis (RA), Crohn's disease (CD), paediatric CD, ulcerative colitis (UC), paediatric UC, psoriatic arthritis (PsA), and psoriasis.
Challenges
- Patent expiration and biosimilar erosion: The impending loss of exclusivity of Cimzia plays a challenging part in the Cimzia drug market and is opportunistic for the biosimilar makers. As the regulatory authorities approve these biosimilar versions of certolizumab pegol, these will be made available at a cheaper cost than the original drug. This cost gap will certainly bring Cimzia with an immense market share erosion among cost-sensitive payers and healthcare providers attracted to more affordable biosimilar alternatives. Hence, the Cimzia's maker will be subjected to immense pressure to hold onto current revenue and volume streams within a growing price-sensitive market space.
- Requirement for specialized storage and handling: The need to structure an apt storage and handling system poses a crucial challenge in the Cimzia drug market. Being a biologic, Cimzia necessitates strict control of the cold chain, stored typically between 2°C to 8°C (36°F to 46°F), to function effectively. Although storage at room temperature (to a maximum of 25°C or 77°F) for a period not exceeding seven to ten days is acceptable, excursions from these conditions may be harmful to the drug's stability. Moreover, the product should be shielded from light. These demanding standards necessitate high-skilled facilities and trained staff at each step of the supply chain.
Cimzia Drug Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
12.5% |
|
Base Year Market Size (2024) |
USD 2.8 billion |
|
Forecast Year Market Size (2037) |
USD 11.5 billion |
|
Regional Scope |
|
Cimzia Drug Segmentation
Indication (Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA))
Based on the indication, the rheumatoid arthritis (RA) segment is expected to dominate with a lucrative share of 45.5% during the projected timeline. It is driven primarily by its established effectiveness, along with extensive clinical evidence to support the use in managing the severe signs and progressive joint damage characteristic of this prevalent autoimmune disorder. For instance, in May 2023, Altamira Therapeutics announced the initiation of a development program based on its proprietary OligoPhore delivery platform and siRNA targeting NF-κB, for a novel generation of rheumatoid arthritis (RA) therapeutics. The Company intended to develop the drug product under project code AM-411 with the objective of out-licensing it at a later stage in accordance with its partnering strategy.
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
Based on distribution channel, one of the most crucial areas of growth in the cimzia drug market is the hospital pharmacies segment. It is driven by their well-rooted network for dispensing specialty drugs that need to be handled and administered using customized procedures in a well-structured healthcare setup. For instance, in July 2022, the biologic medication infliximab was successfully repackaged into a safer, more convenient, and more effective oral capsule by SGS's Quay Pharma in collaboration with Intract Pharma, CPI, and Pharmidex.
Our in-depth analysis of the global cimzia drug market includes the following segments:
|
Indication |
|
|
Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportCimzia Drug Industry - Regional Synopsis
The cimzia drug market in North America is expected its dominate during the forecast timeline, i.e, from 2025 to 2037, with a notable share of 64%. It is notably driven by the rising prevalence of autoimmune diseases such as Crohn's disease and rheumatoid arthritis. Moreover, the strong healthcare systems and government funding guarantee access to innovative therapies. However, due to improvements in healthcare facilities to increased healthcare spending, the region is expected to develop at the fastest rate.
The profitable growth of the U.S. cimzia drug market is propelled by the fostering relations and partnerships between companies for innovation. For instance, in September 2024, to speed up the creation of innovative products, Immune Biopharma and BioTherapeutics, Inc. formed a research partnership. Through access to BioTherapeutics' preclinical services and regulatory capabilities for product testing, mechanism of action validation studies, and the creation of animal and computational models of inflammatory and autoimmune diseases, the partnership enhances NImmune's precision immunology capabilities.
The cimzia drug market in Canada is witnessing significant growth due to smooth regulatory approvals for therapeutic drugs. For instance, in March 2025, Pfizer Canada announced that IXIFI (infliximab for injectable) will be made accessible in Canada from 1st April ‘2025. Health Canada approved it in December 2021 for all the reference product's eligible indications, which included psoriatic arthritis, plaque psoriasis, rheumatoid arthritis, ankylosing spondylitis, Crohn's disease (in adults and children aged 9 and up), fistulizing Crohn's disease, ulcerative colitis (in adults and children aged 6 and up), and psoriatic arthritis.
Asia Pacific Market Analysis
The cimzia drug market in Asia Pacific is gaining traction and is expected to witness lucrative growth during the forecast timeline i.e. 2025-2037 owing to the government programs to increase access to healthcare facilities. Furthermore, collaborations between domestic and foreign companies to disseminate cutting-edge therapies is also propelling the market demand. With further research and development as well as strategic partnerships positioned to open up new markets opportunities and increase medicine accessibility globally, Cimzia's prospects are still bright in the region.
The cimzia drug market in India is expanding as a result of research and development activities being conducted across the health sector. For instance, in February 2025, identifying the necessity of a more effective solution, scientists at Institute of Nano Science and Technology (INST) Mohali have designed a smart system that reacts immediately to the biochemical cues in the inflamed synovial milieu. By focusing on specific inflammatory enzymes found in joints, the system ensures that therapeutic drugs are delivered when necessary, providing a more specific and safer treatment method for RA patients.
The cimzia drug market in China is gaining noteworthy traction owing to the spurred regulatory procedures that facilitates the development of therapeutic drugs to deliver efficacy. For instance, in March 2022, With the approval of three new biosimilars and one for an enlarged indication, China's National Medicinal medications Administration (NMPA) has taken significant steps to enhance access to biosimilar medications for a range of rheumatic illnesses. According to Big Molecule Watch's registry of approved biosimilars in China, the NMPA has approved 24 more biosimilars.
Companies Dominating the Cimzia Drug Landscape
- 3M Company
- UCB S.A.
- LGM Pharma
- ADM
- BASF SE
- Cargill Incorporated
- Land O'Lakes, Inc.
- Dallas Keith
- Agridyne LLC
- Ridley Corporation Limited
- Liquid Feeds Inc.
The cimzia drug market is a dynamic ecosystem that bolster the competitiveness and strategic moves made by eminent key players. This spurs the creation of novel and effective drugs. For instance, in March 2025, a novel Phase 2 study of RHB-204 in Mycobacterium avium subspecies paratuberculosis-positive (MAP+) moderate to severe CD will be initiated using novel endpoints and the new gold standard in imaging techniques, according to RedHill Biopharma Ltd.
Here's the list of some key players:
In the News
- In November 2024, Johnson & Johnson unveiled that 43 presentations including the company's pipeline and portfolio of rheumatology was presented at the American College of Rheumatology (ACR) 2024 Annual Meeting.
- In June 2024, UCB shared findings from three trials for CIMZIA for childbearing-age women with chronic immune-mediated diseases and individuals with rheumatoid arthritis (RA) and elevated rheumatoid factor (RF) levels.
Author Credits: Radhika Pawar
- Report ID: 7610
- Published Date: May 08, 2025
- Report Format: PDF, PPT
